Medgenics
 (MDGN)

- NYSEMKT
What's your position on ?
Bullish
Bearish
Why are you ish?
Skip
Post
You voted ish on Vote again
Posts appear on the My Feed page of subscribers to this ticker
Last vote:
  • Oct. 22, 2015, 10:34 AM
    • Medgenics (MDGN -0.3%) Q3 results: Revenues: $0; R&D Expense: $4.2M (+162.5%); SG&A: $3M (+30.4%); Operating Loss: ($15.4M) (-294.9%); Net Loss: ($16.5M) (-450.0%); Loss Per Share: ($0.66) (-214.3%); Quick Assets: $17.7M (-46.8%).
    • No guidance given.
    | Oct. 22, 2015, 10:34 AM
  • Oct. 22, 2015, 8:05 AM
    • Medgenics (NYSEMKT:MDGN): Q3 EPS of -$0.66
    | Oct. 22, 2015, 8:05 AM
  • Oct. 7, 2015, 6:57 PM
    • Medgenics (NYSEMKT:MDGN) commences a public of common stock. Price, volume and terms have yet to be announced.
    • Shares are unchanged in after hours trading.
    | Oct. 7, 2015, 6:57 PM
  • Oct. 1, 2015, 12:40 PM
    | Oct. 1, 2015, 12:40 PM | 1 Comment
  • Oct. 1, 2015, 9:00 AM
    • Medgenics (NYSEMKT:MDGN) is down 14% premarket on light volume in response to its announcement of a public offering of common stock. Price, volume and terms have yet to be announced.
    | Oct. 1, 2015, 9:00 AM
  • Aug. 10, 2015, 5:03 PM
    • Medgenics (NYSEMKT:MDGN): Q2 EPS of -$0.28 beats by $0.03.
    | Aug. 10, 2015, 5:03 PM
  • Jul. 15, 2015, 8:20 AM
    • Medgenics (NYSEMKT:MDGN) announces that the first patient has been enrolled in a Phase 2 clinical trial evaluating MDGN-201 (TARGTepo) for the treatment of anemia in patients with end stage renal disease undergoing peritoneal dialysis.
    • The primary endpoint of the 12-subject open label study is the maintenance of hemoglobin within the range of 9 - 12 g/dL for 52 weeks. The estimated completion date is September 2017.
    • MDGN-201's technology is called Transduced Autologous Restorative Gene Therapy ((TARGT)). According to the company, TARGT enables greater cell uptake, less immunogenicity, improved safety and tolerability and lower cost than other gene therapies.
    | Jul. 15, 2015, 8:20 AM
  • Jun. 24, 2015, 12:45 PM
    | Jun. 24, 2015, 12:45 PM | 3 Comments
  • Apr. 17, 2015, 8:14 AM
    • Medgenics (MDGN -2.1%) Q1 results: Revenues: $0; R&D Expense: $3.9M (+85.7%); SG&A: $3.9M (+25.8%); Operating Loss: ($7.9M) (-51.9%); Net Loss: ($8.9M) (-64.8%); Loss Per Share: ($0.36) (-28.6%); Quick Assets: $25.2M (-24.3%).
    • No guidance given.
    | Apr. 17, 2015, 8:14 AM
  • Apr. 17, 2015, 8:06 AM
    • Medgenics (NYSEMKT:MDGN): Q1 EPS of -$0.36 misses by $0.16.
    | Apr. 17, 2015, 8:06 AM | 2 Comments
  • Feb. 13, 2015, 8:29 AM
    • Medgenics (MDGN +0.1%) FY14 results: Revenues: $0; R&D Expense: $8.6M (+17.8%); SG&A: $10.7M (+1.9%); Operating Loss: ($18.9M) (-6.2%); Net Loss: ($18.4M) (-7.6%); Loss Per Share: ($1.00) (+5.7%); Quick Assets: $33.3M (+48.7%).
    • No guidance given.
    | Feb. 13, 2015, 8:29 AM
  • Feb. 13, 2015, 8:05 AM
    • Medgenics (NYSEMKT:MDGN): Q4 EPS of -$0.30.
    | Feb. 13, 2015, 8:05 AM
  • Dec. 9, 2014, 5:36 PM
    | Dec. 9, 2014, 5:36 PM
  • Dec. 8, 2014, 12:45 PM
    | Dec. 8, 2014, 12:45 PM | 4 Comments
  • Dec. 5, 2014, 5:40 PM
    • Top gainers, as of 5:15 p.m.: TPLM +4.2%. MDGN +4.1%. REXX +2.4%. AUQ +2.2%. NGD +1.9%.
    • Top losers, as of 5:15 p.m.: ZAYO -2.9%. MORE -2.4%. EFC -2.3%. SN -1.8%. SD -1.7%.
    | Dec. 5, 2014, 5:40 PM | 1 Comment
  • Nov. 25, 2014, 12:45 PM
    | Nov. 25, 2014, 12:45 PM
Company Description
Medgenics Inc is a medical technology and therapeutics company. The Company along with its subsidiaries is engaged in the research and development of products in the field of biotechnology and associated medical equipment.
Sector: Healthcare
Industry: Biotechnology
Country: United States